Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented… read more.
The FDA has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi… read more.
Scientists have, for the first time, identified brain regions outside the frontal lobe involved in the intent to produce speech. The research, published in the Journal of Neural… read more.
People who take over-the-counter pain relievers after a concussion may recover faster than those who do not take pain relievers, according to a preliminary study released today, March… read more.
Severe stress and trauma in childhood have been shown to negatively impact an individual’s health as an adult. Those affected face an increased risk of illness and often… read more.
A little movement could help prevent dementia, even for frail older adults, suggests a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health…. read more.
Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users… read more.
Patients affected by sinus thrombosis are treated with blood thinners. Traditionally, these patients are prescribed vitamin K antagonists (VKAs). In order to give the correct dosage, regular check-ups… read more.
Repurposing amlodipine, a commonly used blood pressure medicine, could help manage attention-deficit/ hyperactivity disorder (ADHD) symptoms, according to an international study involving the University of Surrey. In a… read more.
High intake of lean and oily fish appears to slow the progression of disability in multiple sclerosis (MS), researchers reported on Feb. 25, 2025 in the Journal of Neurology… read more.
Axsome Therapeutics, Inc. announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel… read more.
A new study published today in JAMA Network Open explores the effects of both recent and lifetime cannabis use on brain function during cognitive tasks. The study, the largest of… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
